Photo by nci from unsplash
5074Background: Plasma AR (pAR) gain identifies CRPC with worse outcome on abiraterone (abi) or enzalutamide (enza). We aimed to evaluate whether taxanes in CRPC are active regardless of AR status… Click to show full abstract
5074Background: Plasma AR (pAR) gain identifies CRPC with worse outcome on abiraterone (abi) or enzalutamide (enza). We aimed to evaluate whether taxanes in CRPC are active regardless of AR status ...
Keywords:
status;
plasma;
par;
plasma androgen;
receptor par;
androgen receptor
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!